Daiichi Sankyo and Merck Introduce Breakthrough Ifinatamab Deruxtecan for the Treatment of ES-Small Cell Lung Cancer
Daiichi Sankyo and Merck have introduced ifinatamab deruxtecan as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of adult patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
Ifinatamab deruxtecan (I-DXd) is a specifically engineered B7-H3 directed antibody-drug conjugate (ADC) designed to deliver a topoisomerase I inhibitor payload directly to tumour cells. By targeting B7-H3, a protein highly expressed in small cell lung cancer and associated with poor outcomes, the therapy aims to improve treatment responses in this aggressive disease.
Small cell lung cancer accounts for about 15% of all lung cancer cases worldwide. It is fast-growing, often diagnosed at an advanced stage, and has limited treatment options once standard chemotherapy fails. Five-year survival rates remain low, underlining the urgent need for new therapeutic approaches.
The FDA’s Breakthrough Therapy designation highlights the potential of ifinatamab deruxtecan to address this high unmet medical need. The decision is supported by findings from the Phase 2 IDeate-Lung01 trial, along with supportive evidence from the Phase 1/2 IDeate-PanTumor01 trial, which demonstrated encouraging anti-tumour activity and manageable safety.
Despite existing treatments, extensive-stage small cell lung cancer continues to be associated with poor prognosis and limited survival benefits. The development of ifinatamab deruxtecan represents an important step forward in expanding targeted options for patients.
Ifinatamab deruxtecan is the 'first-and-only' investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of pretreated extensive-stage small cell lung cancer.
